DE60009911D1 - Aminothiazolderivate und ihre verwendung als crf-rezeptor-liganden - Google Patents

Aminothiazolderivate und ihre verwendung als crf-rezeptor-liganden

Info

Publication number
DE60009911D1
DE60009911D1 DE60009911T DE60009911T DE60009911D1 DE 60009911 D1 DE60009911 D1 DE 60009911D1 DE 60009911 T DE60009911 T DE 60009911T DE 60009911 T DE60009911 T DE 60009911T DE 60009911 D1 DE60009911 D1 DE 60009911D1
Authority
DE
Germany
Prior art keywords
receptor ligands
thiazole derivatives
crf receptor
amino thiazole
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60009911T
Other languages
English (en)
Other versions
DE60009911T2 (de
Inventor
Evelyne Fontaine
Michel Geslin
Danielle Gully
Antoine Pradines
Pierre Roger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of DE60009911D1 publication Critical patent/DE60009911D1/de
Application granted granted Critical
Publication of DE60009911T2 publication Critical patent/DE60009911T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
DE60009911T 1999-07-15 2000-07-11 Aminothiazolderivate und ihre verwendung als crf-rezeptor-liganden Expired - Lifetime DE60009911T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9909144A FR2796380B3 (fr) 1999-07-15 1999-07-15 Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
FR9909144 1999-07-15
PCT/FR2000/001995 WO2001005776A1 (fr) 1999-07-15 2000-07-11 Derives d'aminothiazole et leur utilisation comme ligands des recepteurs crf

Publications (2)

Publication Number Publication Date
DE60009911D1 true DE60009911D1 (de) 2004-05-19
DE60009911T2 DE60009911T2 (de) 2005-03-10

Family

ID=9548107

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60009911T Expired - Lifetime DE60009911T2 (de) 1999-07-15 2000-07-11 Aminothiazolderivate und ihre verwendung als crf-rezeptor-liganden

Country Status (36)

Country Link
US (2) US6586456B1 (de)
EP (1) EP1200419B1 (de)
JP (1) JP4949582B2 (de)
KR (1) KR100707320B1 (de)
CN (1) CN1167692C (de)
AR (1) AR024747A1 (de)
AT (1) ATE264315T1 (de)
AU (1) AU772683B2 (de)
BR (1) BR0012478B1 (de)
CA (1) CA2378792C (de)
CO (1) CO5200792A1 (de)
CZ (1) CZ300937B6 (de)
DE (1) DE60009911T2 (de)
DK (1) DK1200419T3 (de)
EA (1) EA005159B1 (de)
EE (1) EE05004B1 (de)
ES (1) ES2220504T3 (de)
FR (1) FR2796380B3 (de)
HK (1) HK1045692B (de)
HU (1) HU229069B1 (de)
IL (2) IL147282A0 (de)
IS (1) IS2314B (de)
ME (1) MEP26608A (de)
MX (1) MXPA02000545A (de)
NO (1) NO324352B1 (de)
NZ (1) NZ516397A (de)
PL (1) PL206515B1 (de)
PT (1) PT1200419E (de)
RS (1) RS50443B (de)
SI (1) SI1200419T1 (de)
SK (1) SK287069B6 (de)
TR (1) TR200200125T2 (de)
TW (1) TWI278453B (de)
UA (1) UA73125C2 (de)
WO (1) WO2001005776A1 (de)
ZA (1) ZA200200221B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303038A2 (hu) * 2000-09-21 2003-12-29 Bristol-Myers Squibb Co. Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EP1423113A4 (de) * 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag Nr1h4-nuklearrezeptorbindende verbindungen
US6993173B2 (en) 2001-10-12 2006-01-31 Duke University Methods for estimating probe cell locations in high-density synthetic DNA microarrays
EP2270034A3 (de) 2004-06-03 2011-06-01 Athlomics Pty Ltd Mittel und Methoden zur Diagnose von Stress
ES2401138T3 (es) * 2004-08-13 2013-04-17 Genentech, Inc. Inhibidores basados en tiazol de enzimas que usan ATP
EP1834641A1 (de) * 2006-03-16 2007-09-19 Sanofi-Aventis CRF1-Rezeptorantagonisten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndromes, und/oder Übergewicht und/oder Dyslipoproteinemie
HUP0900267A2 (en) 2009-04-30 2011-03-28 Sanofi Aventis Process for preparing of thiazole amines and intermediates thereof
WO2013160317A2 (en) * 2012-04-23 2013-10-31 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
EP3096756B1 (de) 2014-01-21 2024-06-12 Neurocrine Biosciences, Inc. Crf1-rezeptor-antagonisten zur behandlung von congenitaler adrenaler hyperplasie
JP2022000473A (ja) * 2018-12-07 2022-01-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
MA54395A (fr) * 2018-12-07 2022-03-16 Neurocrine Biosciences Inc Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
WO2021062246A1 (en) * 2019-09-27 2021-04-01 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
WO2021252669A1 (en) 2020-06-10 2021-12-16 Neurocrine Biosciences, Inc. Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2714059B1 (fr) 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2754258B1 (fr) * 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
KR100707320B1 (ko) 2007-04-13
US8420679B2 (en) 2013-04-16
MEP26608A (en) 2010-06-10
AR024747A1 (es) 2002-10-23
HK1045692B (zh) 2004-11-26
NZ516397A (en) 2004-01-30
EA200101234A1 (ru) 2002-08-29
NO324352B1 (no) 2007-09-24
CA2378792C (en) 2009-11-10
SK382002A3 (en) 2002-07-02
FR2796380B3 (fr) 2001-08-17
PL352901A1 (en) 2003-09-22
TWI278453B (en) 2007-04-11
AU772683B2 (en) 2004-05-06
AU6452100A (en) 2001-02-05
NO20020155L (no) 2002-03-15
CN1370154A (zh) 2002-09-18
PL206515B1 (pl) 2010-08-31
CO5200792A1 (es) 2002-09-27
IL147282A (en) 2008-04-13
JP2003505380A (ja) 2003-02-12
EE200200022A (et) 2003-04-15
HU229069B1 (en) 2013-07-29
DK1200419T3 (da) 2004-07-19
IS6219A (is) 2002-01-03
DE60009911T2 (de) 2005-03-10
EA005159B1 (ru) 2004-12-30
BR0012478B1 (pt) 2013-10-15
IL147282A0 (en) 2002-08-14
WO2001005776A1 (fr) 2001-01-25
SI1200419T1 (en) 2004-08-31
KR20020015373A (ko) 2002-02-27
BR0012478A (pt) 2002-04-02
IS2314B (is) 2007-11-15
TR200200125T2 (tr) 2002-09-23
US20070281919A1 (en) 2007-12-06
ATE264315T1 (de) 2004-04-15
YU1302A (sh) 2005-03-15
EP1200419B1 (de) 2004-04-14
UA73125C2 (uk) 2005-06-15
US6586456B1 (en) 2003-07-01
HUP0202387A2 (hu) 2002-11-28
SK287069B6 (sk) 2009-11-05
RS50443B (sr) 2010-03-02
EE05004B1 (et) 2008-04-15
CZ2002137A3 (cs) 2002-04-17
CN1167692C (zh) 2004-09-22
EP1200419A1 (de) 2002-05-02
CZ300937B6 (cs) 2009-09-16
JP4949582B2 (ja) 2012-06-13
ZA200200221B (en) 2003-04-30
ES2220504T3 (es) 2004-12-16
MXPA02000545A (es) 2002-07-30
CA2378792A1 (en) 2001-01-25
PT1200419E (pt) 2004-07-30
HK1045692A1 (en) 2002-12-06
HUP0202387A3 (en) 2004-12-28
FR2796380A1 (fr) 2001-01-19
NO20020155D0 (no) 2002-01-11

Similar Documents

Publication Publication Date Title
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE69921124D1 (de) Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden
DE60001840T2 (de) Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
DE69836346D1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
DE60006580D1 (de) Benzazolderivate und ihre verwendung als jnk modulatoren
DE60321558D1 (de) Chinolinderivate und deren verwendung als 5-ht6 liganden
ATE371658T1 (de) Purinderivate und ihre verwendung als liganden des cannabinoid rezeptors
DE60039539D1 (de) 4-aminopiperidin-derivate und ihre verwendung als arzneimittel
ATA5422000A (de) Oximderivate und ihre verwendung als latente säuren
ATE252091T1 (de) Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
DE50008597D1 (de) Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
DE69818248D1 (de) Chinolin- und chinazolin-derivate als crf antagonisten
DE60009911D1 (de) Aminothiazolderivate und ihre verwendung als crf-rezeptor-liganden
DE60321958D1 (de) Indazolderivate und ihre verwendung als crf antagonisten
DE60123458D1 (de) Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
DE60037183D1 (de) Neue amidinbenzylamin-derivate und ihre verwendung als thrombin-inhibitoren
ATE221529T1 (de) Oxadiazolinderivate und ihre verwendung als insektizide
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
DE69917777D1 (de) Benzazol-verbindungen und ihre verwendung
DE59806523D1 (de) Substituierte heterocyclische Benzocycloalkene und ihre Verwendung als analgetisch wirksame Substanzen
DE50004104D1 (de) Indolderivate und deren verwendung als 5ht2a liganden
DE50313185D1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
DE60316134D1 (de) Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
DE60008539D1 (de) Substituierte isochinolinderivate und ihre verwendung als anticonvulsiva
DE69718850D1 (de) Heterocyclische N-Acetonylbenzamide und ihre Verwendung als Fungizide

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1200419

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE